Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 149Breast Neoplasms 38Prostatic Neoplasms 31Insulin Resistance 30Obesity 23Endometrial Neoplasms 15Neoplasms 14Infertility 14Colorectal Neoplasms 13Pancreatic Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Anovulation 10Lung Neoplasms 9Neoplasm Metastasis 8Hyperandrogenism 8Glioblastoma 8Diabetes Mellitus 8Squamous Cell Carcinoma of Head and Neck 7Metabolic Syndrome 7Melanoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Head and Neck Neoplasms 5Brain Neoplasms 5Adenocarcinoma 5Weight Loss 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Rectal Neoplasms 4

Interventions

Irinotecan 2Injections 2vistusertib 1urelumab 1sapanisertib 1pembrolizumab 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1atezolizumab 1ZD4054 1Topotecan 1Tiragolumab 1Rosuvastatin Calcium 1Radiotherapy 1Rabeprazole 1Metformin 1HM781-36B 1Furosemide 1Digoxin 1ATP Binding Cassette Transporter, Subfamily B, Member 1 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Malignancies × Metformin × Clear all
NCT06899061 2026-03-27

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

AstraZeneca

Phase 1 Active not recruiting
41 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡